HealthDay on MSN1d
FDA Approves Ebglyss for Moderate-to-Severe Atopic Dermatitis
The U.S. Food and Drug Administration has approved Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 years and ...
clinicaladvisor.com2d
Ebglyss Approved for Moderate to Severe Atopic Dermatitis
The Food and Drug Administration (FDA) has approved Ebglyss™ (lebrikizumab-lbkz) for the treatment of adult and pediatric ...
Eli Lilly Scores FDA Approval For Eczema Treatment Ebglyss
The FDA has approved Eli Lilly's Ebglyss for moderate-to-severe eczema in patients 12 and older. The treatment is ...
The American Journal of Managed Care3d
FDA Approves Lebrikizumab For Patients Aged 12 and Older With Moderate to Severe Atopic Dermatitis
The FDA has approved lebrikizumab (Ebglyss; Eli Lilly) as a new first-line biologic treatment for patients aged 12 and older ...
The EMBO Journal10d
Gene therapy for epilepsy targeting neuropeptide Y and its Y2 receptor to dentate gyrus granule cells
Co-expressing NPY and its inhibitory receptor Y2 in excitatory hippocampal cells allows inhibitory autoregulation of ...